Methods for treating inflammatory skin conditions (minocycline)
USPTO granted Journey Medical Corporation Patent US12594252B2 covering methods of treating inflammatory skin conditions using reduced-dose minocycline compositions. The patent, with 39 claims, names six inventors including Swati Kulkarni and Rajeev Singh Raghuvanshi. The invention relates to administering a pharmaceutical composition comprising a reduced dose of minocycline to achieve effective plasma or interstitial fluid concentrations for treating inflammatory skin conditions.
Benzalkonium Chloride for Treating COVID-19 and Conjunctivitis
USPTO granted patent US12594251B2 to Bausch + Lomb Ireland Limited on April 7, 2026, covering methods of treating COVID-19 (including ocular manifestations) and conjunctivitis using benzalkonium chloride, as well as methods for reducing COVID-19 transmission using the compound. The patent, with inventors Patrick McCormick and Kimberly Millard, contains 40 claims and is classified under CPC codes A61K 31/14, A61P 27/02, and A61P 31/14.
Small molecule compounds for treating lung epithelial and vascular endothelial cell injury
USPTO granted patent US12594282B2 to Guangzhou Cellprotek Pharmaceutical Co., Ltd. on April 7, 2026. The patent covers the use of 5α-androst-3β,5,6β-triol and analogues for treating pulmonary diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury. The compounds inhibit PFKFB3 expression and reduce vascular endothelial and alveolar epithelial cell injury.
SCYNEXIS patent for triterpenoid antifungals treating Pneumocystis pneumonia
The USPTO issued patent US12594266B2 to SCYNEXIS, INC. on April 7, 2026, covering eufumafungin derivative triterpenoid antifungal compounds and their use in treating or preventing Pneumocystis pneumonia (PCP). The patent includes 16 claims encompassing the compound structures, pharmaceutical compositions, and methods of treatment.
Cambridge Cognition Patent - Combination Therapy for Schizophrenia
The USPTO granted Patent US12594270B2 to Cambridge Cognition Limited on April 7, 2026. The patent covers a combined therapy comprising alpha-7 nicotinic acetylcholine receptor activators with 5-HT3 receptor inhibitory activity combined with 5-HT3 receptor activators for treating schizophrenic disorders. The patent contains 21 claims and names Kiri Granger and Jennifer Barnett as inventors.
Mitochondria-targeted atovagone compounds and methods for antitumor, antimicrobial, and antimalarial treatment
USPTO granted Patent US12594283B2 to The Medical College of Wisconsin, Inc. covering mitochondria-targeted Atovaquone compounds (Mito-ATO) and methods of using such compounds for antitumor, antimicrobial, and antimalarial treatment. The patent contains 22 claims and was filed on October 26, 2020.
Patent US12594280B2: Antiviral Compositions for Influenza Treatment
USPTO granted Patent US12594280B2 to Universite Claude Bernard Lyon 1 covering antiviral pharmaceutical compositions containing Etilefrine and Diltiazem for preventing and treating influenza virus infections. The patent includes 10 claims and covers the use of these compounds in veterinary and pharmaceutical compositions.
Patent B2, cardioembolic stroke diagnosis via chest X-rays
The USPTO granted Patent US12594046B2 to Seoul National University Hospital on April 7, 2026. The patent covers a method and apparatus for assisting diagnosis of cardioembolic stroke using chest radiographic images analyzed by a neural network model. Inventors are Han-Gil Jeong and Tackeun Kim.
Radiographic imaging apparatus and control method thereof
USPTO granted Canon Kabushiki Kaisha Patent US12594049B2 for a radiographic imaging apparatus with radiation detection and communication control capabilities. The patent covers a system that stores radiographic imaging data when communication with a control apparatus is abnormal and transmits stored data once communication is restored.
Surgical instrument with needle holder for bone anchor insertion device
USPTO granted patent US12594065B2 to BIEDERMANN TECHNOLOGIES GMBH & CO. KG for a surgical instrument connectable to a bone anchor insertion device. The instrument includes a handle portion, needle holder, actuator, and transmission member to convert rotational movement into axial needle advancement and retraction.
Posterolateral Instrumentation Treatment System and Methods - Spinal Surgery Patent
The USPTO granted patent US12594098B2 to the Board of Trustees of the University of Illinois for a posterolateral instrumentation treatment system and methods for spinal surgery. The patent covers a spinal fixation system including a cannulated bone rod designed for controlled fluid delivery to bone and surrounding tissue during surgical procedures. Key claims include a bone screw with longitudinal access, a bone rod positioned laterally to the longitudinal axis, and methods for delivering fluids or using the fixation system as a drainage point for posterolateral fusion sites. The patent has 19 claims with CPC classifications A61B 17/7017 and A61B 17/7002.
Endoscope System and Coordinate System Correction Method
USPTO granted Patent US12593962B2 to Olympus Corporation covering an endoscope system with automated coordinate correction. The patent describes methods for detecting endoscope movement direction, estimating moving body areas in captured images, and calculating deviations between endoscope and moving device coordinate systems to enable automatic correction.
$3.2M DEA Settlement Should Caution Hospitals on Controlled-Substance Recordkeeping
The DEA reached a $3.2 million settlement with Sutter Medical Center, Sacramento and Sutter Fairfield Surgery Center to resolve 628 alleged violations of Controlled Substances Act recordkeeping and security requirements. SMCS faced 360 violations including failures to link CSOS records and notify DEA of theft/loss; SFSC faced 268 violations spanning recordkeeping, inventory, and security failures. The settlement underscores federal enforcement focus on holding healthcare providers accountable for safeguarding controlled substances against theft and diversion.
100% tariffs on patented pharmaceuticals, key exemptions detailed
100% tariffs on patented pharmaceuticals, key exemptions detailed
Healthcare & Life Sciences: Drug Pricing Digest - April 2026
President Trump issued a proclamation under Section 232 imposing 100% ad valorem tariffs on imported patented pharmaceuticals and associated ingredients. Companies with approved onshoring plans receive a reduced 20% rate (rising to 100% after 4 years), while those negotiating Most Favored Nation pricing agreements with HHS may qualify for exemptions. Reduced rates of 10-15% apply to products from EU, Japan, South Korea, Switzerland, Liechtenstein, and the UK under existing trade commitments.
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule
Holland & Knight LLP summarizes CMS final rule for CY 2027 Medicare Advantage and Part D, effective June 1, 2026. The rule codifies Inflation Reduction Act-driven Part D redesign including out-of-pocket caps and manufacturer discount programs, while finalizing Star Ratings reforms and TPMO oversight updates. CMS also clarifies that cannabis products illegal under federal or applicable state law cannot be offered as SSBCI.
Antitrust Enforcers Intensify Scrutiny of Healthcare Algorithmic Pricing
At the ABA Antitrust Spring Meeting, a panel discussed the intensifying scrutiny of algorithmic pricing tools in healthcare and data-driven industries. The Department of Justice Antitrust Division continues to file Statements of Interest emphasizing the 'starting point' theory, asserting that competitors may coordinate simply by agreeing to use the same algorithm to generate benchmark prices. California Assembly Bill 325 (AB 325), effective January 1, 2026, prohibits the use of 'common pricing algorithms' that use competitor data to stabilize prices or wages, introducing potential criminal liability for coercive conduct.
Office of Rural Health Transformation and Sustainability established
Governor Jeff Landry signed an executive order establishing the Office of Rural Health Transformation and Sustainability within the Louisiana Department of Health. The new office will oversee implementation of Louisiana's Rural Health Transformation Program with over $208 million in federal funding, potentially drawing down more than $1 billion over five years. An advisory council will guide implementation and ensure efforts align with statewide priorities.
Group A Strep outbreak West Hawaii, investigation underway
The Hawaii Department of Health and CDC are investigating elevated rates of invasive Group A Streptococcus (iGAS) infections in West Hawaii. The investigation began after a local physician reported higher-than-expected cases over several months. DOH routinely monitors these infections, and Hawaii has historically had higher rates than the national average. Investigators aim to confirm whether cases are increasing, identify risk factors, evaluate disease reporting, and understand how infections are occurring in the community.
DOH Urges Parents of Seventh-Grade Students to Schedule Checkup Visits
The Hawaii Department of Health issued a public reminder on April 7, 2026, urging parents to schedule well-child visits for students entering seventh grade before the 2026-2027 school year. Hawaii law requires students to submit documentation of a physical exam and required vaccinations (Tdap, MCV, HPV) or have an approved exemption. The notice highlights rising pertussis cases in Hawaii, which increased from 3 cases in 2023 to 252 cases in 2025.
Hydroflumethiazide composition for treating TNF-α-related diseases
USPTO granted Patent US12594279B2 to SK Chemicals Co., Ltd. for a composition containing hydroflumethiazide as an active ingredient for preventing or treating TNF-α-related diseases. The patent covers formulations effective at inhibiting TNF-α expression, demonstrating superior efficacy compared to methotrexate and hydroxychloroquine for rheumatoid arthritis treatment. The patent includes 8 claims and covers CPC classifications related to pharmaceutical compositions.
LILRB2 Antibodies and Uses Thereof - Cancer and Autoimmune Treatment
The USPTO granted patent US12596122B2 to The Board of Regents of the University of Texas System covering LILRB2 antibodies and their uses for detecting and treating cancer and autoimmune diseases. The patent names 11 inventors and includes 26 claims. The filing date was January 28, 2021, under application number 17759800.
Methods of treating psoriasis with secukinumab
The USPTO granted patent US12594332B2 to Novartis AG covering novel regimens for treating psoriasis using secukinumab, an IL-17 antibody antagonist. The patent includes 11 claims directed to therapeutic methods employing the antibody. The patent application was filed on December 16, 2024, with inventors including Achim Guettner, Matthias Machacek, Charis Papavassilis, and Oliver Sander.
IL-17 antagonist compositions for treating inflammatory arthritis
USPTO granted patent US12594333B2 to Novartis AG covering methods of treating inflammatory arthritis using IL-17 antagonists, specifically IL-17 binding molecules such as secukinumab antibodies. The patent contains 16 claims and covers therapeutic regimens for conditions including psoriatic arthritis.
Bexagliflozin extended-release tablet, SGLT2 inhibitor formulation
The USPTO granted patent US12594243B2 to TheracosBio, LLC for an extended-release tablet formulation of the SGLT2 inhibitor bexagliflozin. The patent covers formulations designed to achieve lower peak plasma concentrations (Cmax) compared to immediate-release forms while maintaining therapeutic drug levels over extended periods. The patent contains 7 claims and provides intellectual property protection for the drug delivery technology through 2040.
BOL-148 substance abuse treatment method patent grant to Ceruvia Lifesciences
The USPTO granted patent US12594272B2 to Ceruvia Lifesciences LLC covering a method of treating substance abuse using 2-bromo-lysergic acid diethylamide (BOL-148). The patent contains 6 claims and was filed on March 25, 2021, with Carey Turnbull listed as the inventor.
Rhamnolipid compositions with antibiotics, UNC Chapel Hill patent
The USPTO granted patent US12594289B2 to The University of North Carolina at Chapel Hill on April 7, 2026, covering compositions combining biosurfactants (rhamnolipids) with antibiotics to enhance antibacterial potency against infections. The patent includes 18 claims and names Brian Conlon, Sarah Conlon, and Lauren Radlinski as inventors.
Prevention of tolerance to stimulant ADHD medication
USPTO granted patent US12594250B2 to James Martin Swanson for methods of preventing accumulated tolerance to stimulant medication used in ADHD treatment. The patent discloses pharmaceutical compositions with controlled-release formulations combining immediate-release and sustained-release components to counteract acute tolerance. The patent contains 16 claims covering methods of treatment using ascending delivery profiles.
US12594055B1 probe apparatus, Big Ridge Solutions, 7th Apr
US12594055B1 probe apparatus, Big Ridge Solutions, 7th Apr
Gender-specific mesh implant with barrier for inguinal hernia repair
USPTO granted Patent US12594153B2 to Hexagon Health, Inc. on April 7, 2026. The patent covers a gender-specific implantable mesh for inguinal hernia repair featuring an anti-adhesive barrier configured to prevent direct contact with the spermatic cord and genital nerve, and a keyhole designed to accommodate these structures without constriction. The invention includes 22 claims covering the mesh structure and its oblique positioning relative to centerlines.
Aqueous humor drainage device with adjustable tube diameter for glaucoma
USPTO granted Patent US12594186B2 to The Catholic University of Korea Industry-Academic Cooperation Foundation for an aqueous humor drainage device with adjustable tube diameter for glaucoma treatment. The device comprises an annular outer tube and inner tube made of biodegradable material with a shrinkage hole, designed to be inserted into the eyeball to drain aqueous humor externally. The patent contains 13 claims and was filed on June 28, 2021.
Universal broach system for humeral implants - Patent Grant
The USPTO granted Patent US12594083B2 to Zimmer, Inc. for a universal broach system designed for preparing bone to receive humeral prosthesis anchors. The patent covers a distal broach component with radially extending cutting spokes and a proximal broach component with spacer spokes in an interval pattern. The 12-claim patent was filed on October 9, 2023.
OrthoPediatrics Osteotomy Device Patent Granted
USPTO granted patent US12594100B2 to OrthoPediatrics Corp. covering osteotomy devices and methods including bone plates, bridging devices, and spreading mechanisms with 18 claims. The patent relates to surgical tools for performing osteotomies with scissors-type spreading mechanisms and ergonomic designs.
Implant stability sensor system and method
USPTO granted patent US12594029B2 to OrthoIQ, LLC for an implant stability sensor system designed to detect motion between an implant and bone. The patent covers a system with bone locator means, implant attachment means with detection capabilities, and data analysis means. The patent includes 20 claims and was assigned CPC classifications related to medical implants and sensor technologies.
Substituted pyrazolo piperidine carboxylic acids
USPTO granted patent US12595247B2 to Bayer Aktiengesellschaft covering substituted pyrazolo piperidine carboxylic acids, their salts, and processes for preparation. The patent includes 6 claims and lists 18 inventors. The compounds are directed toward cardiovascular and cardiac diseases, including heart failure with reduced, mid-range, and preserved ejection fraction.
MET Kinase Inhibitor Patent US12595245B2 Granted
The USPTO granted patent US12595245B2 to Celyn Therapeutics, Inc. covering MET receptor tyrosine kinase inhibitor compounds, pharmaceutical compositions, and methods of use for treating disease. The patent contains 18 claims and is classified under CPC codes C07D 401/12, C07D 215/22, C07D 405/14, and C07D 471/04. This grant establishes enforceable intellectual property rights for the disclosed MET kinase inhibitors.
Inhibitors of SARM1 for Axonal Degeneration Treatment
USPTO granted patent US12595252B2 to DISARM Therapeutics, Inc. on April 7, 2026, covering SARM1 inhibitor compounds and methods for treating axonal degeneration. The patent includes 4 claims and covers specific chemical compositions useful in neurological disease treatment.
PRMT5 inhibitors for cancer treatment
USPTO granted patent US12595248B2 to Merck Sharp & Dohme LLC covering PRMT5 inhibitor compounds of Formula I and their use in treating cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent includes 32 claims covering the compound compositions, methods of making, pharmaceutical formulations, and treatment methods.
Pedestrian Safety Awareness Campaign Launched by NY DOH
The New York State Department of Health announced a $2.5 million media campaign to raise awareness about pedestrian safety best practices for drivers and pedestrians. The campaign is conducted in partnership with the Governor's Traffic Safety Committee and the New York State Department of Transportation, responding to over 65,000 pedestrian injuries and 1,000 fatalities since 2020.
Variance Approval Letter to Primo Entertainment Inc
FDA's Center for Devices and Radiological Health (CDRH) approved a variance request from Primo Entertainment Inc, granting the company relief from specific regulatory requirements under federal standards for electronic products or radiation-emitting devices. The variance pertains to the company's entertainment products that fall under FDA's radiation safety jurisdiction.
Amended Citizen Petition - Insulin Detemir Drug Shortage and Biosimilarity Guidance
Alliance to Protect Insulin Choice submitted amendments to its citizen petition requesting FDA to declare insulin detemir a medically necessary drug in shortage, provide guidance on demonstrating biosimilarity for withdrawn drugs, and permit 503B outsourcing facilities to compound the drug. The petition addresses access concerns following detemir's withdrawal from the U.S. market.
FDA Issues Priority Review Voucher for LOARGYS (pegzilarginase-nbln)
The FDA announced issuance of a priority review voucher to Immedica Pharma AB for LOARGYS (pegzilarginase-nbln), approved February 23, 2026. The drug treats hyperargininemia in adults and pediatric patients 2 years and older with Arginase 1 Deficiency. The voucher was awarded under section 529 of the FD&C Act for rare pediatric disease products meeting specified criteria.
CDER Interim Response Letter to Age Reversal Unity
FDA CDER issued an interim response letter to Age Reversal Unity regarding submission FDA-2025-P-4985, a Pre-Request for Designation (Pre-IND or similar drug development query). The letter provides preliminary feedback or requests additional information but does not constitute a final regulatory determination. The company must address agency concerns before a final response is issued.
FDA Center for Tobacco Products Complaint Document
The FDA Center for Tobacco Products (CTP) filed a formal complaint document on April 7, 2026, via Regulations.gov docket FDA-2026-H-3303. The complaint, authored by CTP staff, initiates an enforcement proceeding against one or more regulated entities for alleged violations of federal tobacco product regulations. The specific allegations and parties involved are contained in the attachment but are not accessible for review in this summary.
FDA Administrative Practices and Procedures Information Collection Comment Request
The FDA published a notice in the Federal Register announcing an opportunity for public comment on a proposed information collection under the Paperwork Reduction Act of 1995. The collection covers general FDA administrative practices and procedures, including requests for formal hearings. Comments must be submitted by June 8, 2026 via regulations.gov or mail.
E2B(R3) Data Standards for Postmarketing Individual Case Safety Reports
FDA announces updated data standard requirements for postmarketing individual case safety reports (ICSRs) for human drug products, biological products, and drug- or biologic-led combination products. Starting October 1, 2026, all ICSR submissions to the FDA Adverse Event Monitoring System (AEMS) database via the Electronic Submissions Gateway Next Generation must use ICH E2B(R3) data standards, replacing the current E2B(R2) standard. The public comment period closes October 1, 2025.
FDA CTP Complaint - No Documents Available
The FDA Center for Tobacco Products (CTP) filed a formal complaint (FDA-2026-H-3091-0001) on regulations.gov. The docket indicates that a complaint has been initiated, though the underlying documents are not available for viewing. This represents a formal enforcement action by FDA's tobacco regulatory division against one or more regulated parties.
Variance Application - Primo Entertainment Inc
FDA received a variance application from Primo Entertainment Inc (New York) on March 13, 2026. The application was submitted to the Center for Devices and Radiological Health (CDRH) for review. No associated documents are currently available for public viewing on the regulatory docket.
FDA confirms STRATTERA not withdrawn for safety
FDA confirms STRATTERA not withdrawn for safety
FDA Suitability Petition Amendment - Hyman Phelps & McNamara
Law firm Hyman, Phelps & McNamara, P.C. filed an amendment to a suitability petition with FDA's Center for Drug Evaluation and Research (CDER). The petition seeks a regulatory determination regarding drug product suitability under the Federal Food, Drug, and Cosmetic Act. FDA will review the amended petition and issue a determination on whether the requested drug product meets suitability requirements for approval pathways.
FDA Complaint - Tracking mno-s34f-ax16
FDA received a complaint filed on April 7, 2025, tracked under identifier mno-s34f-ax16 (docket FDA-2026-H-3442-0001). The complaint was submitted by CTP (Center for Tobacco Products) and is accessible via regulations.gov. No documents are currently available for viewing or download from the docket.
Prosthesis for Lung and Treatment Method for Pulmonary Fibrosis
The USPTO granted Patent US12594156B2 to National Institute of Biological Sciences, Beijing for a lung prosthesis designed to treat pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The patent covers 16 claims and was filed on May 30, 2019. This grant confers exclusive intellectual property rights to the assignee for the prosthetic device and associated treatment methods.
Hybrid braided stent, US12594154B2, 7th Apr
Hybrid braided stent, US12594154B2, 7th Apr
Expandable interbody spinal prosthesis
USPTO granted patent US12594169B2 to MiRus LLC for an expandable interbody device used as a prosthesis during spinal surgery. The device includes a drive block, linkage block, drive screw, first and second endplates, and linkages configured to provide spinal stability. The patent contains 30 claims.
Hernia repair, breast reconstruction and sling devices containing poly(butylene succinate)
USPTO granted patent US12594361B2 to Tepha, Inc. on April 7, 2026, covering resorbable implants made from poly(butylene succinate) and copolymers for hernia repair, breast reconstruction, and sling devices. The patent includes 17 claims and covers sterilized devices with specific endotoxin requirements, oriented fibers, meshes, and 3D-printed forms. The technology also includes receptacles for cardiac rhythm management devices such as pacemakers and neurostimulators.
System and method for implantable muscle interface
The USPTO granted Patent US12594172B2 to Johns Hopkins University for an implantable human-machine interfacing system that captures electromyographic signals from muscles and provides sensory feedback through electrical stimulation. The system includes sensors, amplifiers, a transceiver for wireless transmission to an external decoder, and an implantable power source for neuromodulation. The patent covers applications in prosthetics and assistive devices.
Orthotic and Prosthetic Device and Manufacturing System and Method
USPTO granted patent US12594173B2 to Hanger, Inc. for an orthotic and prosthetic device including a socket, fasteners, and pylon system. The patent covers the mechanical coupling design between socket components and pylon through threaded fasteners extending through aligned through-holes and blind-holes. This patent affects medical device manufacturers developing prosthetic limbs.
Robotic system for shoulder arthroplasty using stemless implant components
USPTO granted patent US12594171B2 to Howmedica Osteonics Corp. covering robotic systems and methods for shoulder arthroplasty. The patent describes a guidance station that tracks surgical tools, patient humerus, and scapula to control tool movement relative to virtual cutting boundaries for bone preparation. The system positions implants based on bone density characteristics.
Glaucoma Shunts and Related Methods of Use - US12594187B2
USPTO granted patent US12594187B2 to Hexiris Inc. for glaucoma shunts and associated methods of use. The patent covers elongate bodies with inner walls defining lumens for draining aqueous humour to decrease intraocular pressure in eyes. The patent contains 8 claims and is classified under CPC codes A61F 9/00781 and related ophthalmic categories.
Fc Variants and IL-8 Antibodies Patent Grant
USPTO granted patent US12595299B2 to Chugai Seiyaku Kabushiki Kaisha covering Fc region variants with improved antigen binding in ion concentration-dependent manner, Fc variants with decreased binding to pre-existing anti-drug antibodies, and novel IL-8 antibodies for pharmaceutical use. The patent contains 17 claims and covers molecules derived from antibody engineering technology.
Methods to Decrease Impurities from Recombinant Protein Manufacturing Processes
The USPTO granted Patent US12595294B2 to Hoffmann-La Roche Inc. on April 7, 2026. The patent covers methods for reducing non-aggregate produce-related impurities (NAPRIs) in buffered solutions of monoclonal antibodies using synthetic depth filters. Inventors are Marc Pompiati and Christoph Feistl, with 15 claims in the granted patent.
Vasopressin-2 receptor antagonist peptides and uses thereof
The USPTO has granted Patent US12595288B2 to Commissariat à l'Énergie Atomique et aux Énergies Alternatives covering vasopressin-2 receptor antagonist peptides. The patent protects peptide sequences with at least 80% amino acid identity to SEQ ID NO. 1, with specific modifications at variable positions enabling therapeutic applications. The grant includes 14 claims.
Anti-NGF Antibody and Antigen-Binding Fragment Patent Grant
USPTO granted Patent US12595298B2 to XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD. for an anti-NGF antibody and its antigen-binding fragment, covering the preparation method and therapeutic applications for NGF-mediated diseases. The patent includes 6 claims and was filed on August 2, 2021.
LMP-1 Expressing Cells and Methods of Use Thereof - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute, Inc. has been granted USPTO Patent US12595285B2 covering immunogenic cells expressing LMP1 and methods of use for cancer treatment and T cell activation. The patent, with 15 claims, names Baochun Zhang, Il-Kyu Choi, and Zhe Wang as inventors, with an application filing date of May 13, 2022.
Anti-human P40 protein domain antibody and use thereof
USPTO granted Patent US12595300B2 to Akeso Biopharma, Inc. covering an anti-human P40 protein domain antibody for treating autoimmune diseases. The patent includes 20 claims with specific amino acid sequences for heavy and light chain variable regions (SEQ ID NOs 1, 24 for heavy chain; SEQ ID NOs 6, 11, 13, 15, 17, 25 for light chain).
Heterocyclic GLP-1 agonists
USPTO granted patent US12595264B2 to Gasherbrum Bio, Inc. on April 7, 2026, covering heterocyclic GLP-1 receptor agonists of Formula (I), including pharmaceutical salts, solvates, and compositions. The patent names six inventors and contains 24 claims, with CPC classifications spanning heterocyclic chemistry (C07D 487/04), phosphorus compounds (C07F 9/6561), and pharmaceutical formulations (A61K 31/4985, A61K 38/26).
PRMT5 inhibitors for cancer, sickle cell, and HPFH treatment
USPTO granted patent US12595262B2 to Merck Sharp & Dohme LLC for PRMT5 inhibitor compounds and methods of treatment for cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent covers 14 claims including compounds A through D and their pharmaceutical salts, esters, and prodrugs.
P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims
P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims
NEC patent for endoscopic lesion detection using heat maps
NEC patent for endoscopic lesion detection using heat maps
Apparatus and Methods for Screening, Diagnosis and Monitoring of Respiratory Disorders
The USPTO granted ResMed Pty Ltd Patent US12594025B2 covering a medical device that uses ECG sensors, accelerometers, and photoplethysmographs (PPG) to detect sleep-disordered breathing (SDB) events. The patent includes 20 claims and covers methods for screening, diagnosis, and monitoring of respiratory disorders using multi-sensor signal analysis.
Endoscope with Fluid Flow Circuit Closure Device for Improved Sterilisation
The USPTO granted patent US12593960B2 to AXESS VISION TECH for a medical endoscope featuring a piston-based fluid flow circuit closure device. The invention includes a sealed obturation section and interconnection chamber designed to limit pressure drop during circuit operation. The patent covers 11 claims and protects the assignee's proprietary fluid closure mechanism intended to improve sterilisation of endoscopic equipment.
Endoscope Treatment Tool - US12593959B2
USPTO granted patent US12593959B2 to Olympus Medical Systems Corp. for an endoscope treatment tool featuring a sheath with a first channel and an incision device with a second channel. The invention enables switching between two modes to form different fluid paths between the main flow chamber and the respective channels. The patent contains 13 claims.
Method and system for assisting a user in guiding a catheter during a cardial operation
The USPTO granted Patent US12594018B2 to Biosense Webster (Israel) Ltd. for a method and system assisting catheter guidance during cardiac procedures. The patent covers dynamically identifying displaced portions of a catheter distal end assembly using electrical information from electrodes, generating and warping visual representations for display. The patent contains 20 claims and was filed on May 20, 2024.
NSCLC brain metastasis survival prediction method patent granted
USPTO granted patent US12594024B2 on April 7, 2026, to THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a method of predicting survival of non-small cell lung cancer patients with brain metastasis. The patent covers comparing patient TMTrg values against cut-off values for long-term survival prediction using medical imaging analysis.
Medtronic Patent - Atrial Tachycardia Detection Based on Cardiac Rhythm Regularity
The USPTO granted Medtronic patent US12594019B2 covering systems and methods for detecting atrial tachycardia (AT) by analyzing cardiac rhythm regularity. The patent discloses techniques that apply different AT detection criteria depending on whether heart beat intervals are determined to be regular or irregular, enabling more accurate identification of AT episodes.
CoMind Technologies iNIRS System Patent Granted
USPTO granted Patent US12593983B2 to CoMind Technologies Limited for an interferometric near infrared spectroscopy (iNIRS) system. The patent covers a light emitting arrangement with wavelength swept emission, a light detecting arrangement with an interferometric optical detector, and multiple optical channel paths for delivering sample and reference light. The patent contains 20 claims and is classified under CPC codes including A61B 5/0075 and G16H 40/63.
Medical stroboscope endoscopy system with rolling shutter image sensor
USPTO granted patent US12593970B2 to KARL STORZ Imaging, Inc. for a medical stroboscope endoscopy system utilizing rolling shutter image sensors with strobe light pulsing. The patent covers methods and devices for combining subset image data from adjacent rolling-shutter frames into enhanced video frames for endoscopic imaging applications.
Substituted pyrimidine radical quenchers, Arizona State University
Substituted pyrimidine radical quenchers, Arizona State University
T cell receptors for mesothelin cancer immunotherapy
The USPTO granted patent US12595290B2 to Fred Hutchinson Cancer Center covering binding proteins (T cell receptors) specific for mesothelin peptides Msln20-28 and Msln530-538, along with compositions and recombinant host cells for cancer immunotherapy. The patent protects methods for treating mesothelioma, pancreatic cancer, ovarian cancer, and lung cancer using these binding proteins.
BIG3-PHB2 Interaction-Inhibiting Peptide Therapeutic Agent for Breast Cancer
USPTO granted patent US12595289B2 to Tokushima University for a therapeutic peptide that inhibits BIG3-PHB2 protein interaction, designed specifically for treating estrogen receptor-positive breast cancer. The peptide selectively targets BIG3-overexpressing cancer cells while avoiding expression of side effects. The patent covers 6 claims including the peptide composition and pharmaceutical formulation.
Anti-follicle stimulating hormone receptor antibodies and methods of treatment
USPTO granted Patent US12595293B2 to The Wistar Institute covering isolated antibodies and antigen-binding fragments that specifically bind to Follicle Stimulating Hormone Receptor (FSHR), along with methods for treating diseases by administering these antibodies. The patent includes 14 claims and covers compositions for cancer treatment applications.
Dosing regimes for treatment of synucleinopathies
USPTO granted patent US12595295B2 to Prothena Biosciences Limited covering antibody dosing regimes for treatment of synucleinopathies. The patent specifies intravenous antibody dosing of 3000-5000 mg or 1300-1700 mg every 3-5 weeks. This grant provides exclusive intellectual property rights for these therapeutic dosing protocols.
Fluorine-containing compound and anti-cancer medical use thereof
The USPTO granted patent US12595275B2 to Ascentawits Pharmaceuticals, Ltd. on April 7, 2026, covering a fluorine-containing compound (Formula II/III) with anti-cancer medical applications. The patent claims novel structures incorporating trifluoromethyl groups and fluorine-substituted aryl or heteroaryl groups at specific positions, with 17 total claims.
Aminopyridine compound as aldehyde trapping agent
USPTO granted Patent US12595259B2 to Zhuhai United Laboratories Co., Ltd. for an aminopyridine compound functioning as an aldehyde trapping agent, including formula (I) and its pharmaceutically acceptable salts. The patent covers 18 claims and has applications in ophthalmic therapeutics.
Amidines and amidine analogs for bacterial infection treatment
The USPTO granted Patent US12595251B2 to Georgia State University Research Foundation, covering amidine compounds and methods for treating bacterial infections or potentiating antibiotics. The patent names Binghe Wang, David W. Boykin, Manjusha Roy Choudhary, Arvind Kumar, Bingchen Yu, and Mengyuan Zhu as inventors. The patent, with 10 claims, covers CPC classifications including C07D compounds and A61P 31/04 (anti-infectives).
FinCEN Healthcare Fraud Advisory - 24 Red Flags and Enhanced Reporting
FinCEN issued an advisory on March 30, 2026, urging financial institutions to be vigilant in identifying and reporting suspicious transactions related to healthcare fraud schemes targeting Medicare, Medicaid, and other federal and state health care benefit programs. The advisory applies broadly to banks, broker-dealers, investment companies, insurance companies, and certain real estate businesses, providing 24 red flag indicators for identifying fraud and money laundering activity. Financial institutions are encouraged to voluntarily report suspicious activity and notify law enforcement regarding fraud schemes targeting Health Care Benefit Programs.
CMS Proposes Skilled Nursing Facilities Payment Updates for FY 2027
CMS has published a proposed rule (CMS-1843-P) updating the Skilled Nursing Facility Prospective Payment System rates and policies for fiscal year 2027. The rule also proposes updates to the SNF Quality Reporting Program and SNF Value-Based Purchasing Program requirements. Comments must be submitted by June 1, 2026.
ASP Data Submission Notice for Medicare Part B Drugs - Comments Closed May 7
CMS published a 30-day Paperwork Reduction Act notice announcing revision of an existing collection for manufacturer submission of Average Sales Price (ASP) data for Medicare Part B drugs and biologicals. The notice revises the Bona Fide Service Fee Certification form and updates burden estimates. Comments on the information collection must be received by the OMB desk officer by May 7, 2026.
Medicare Prior Authorization WISeR Model Correction Notice
CMS issued a correction notice to fix typographical and technical errors in the July 1, 2025 Federal Register notice about the WISeR (Wasteful and Inappropriate Services Reduction) Model for Medicare prior authorization. The corrections update specific lists of procedure codes for epidural steroid injections, vertebral compression fracture procedures, fusion procedures, and apnea treatments, while also clarifying applicability language for skin and tissue substitutes. The corrections are effective April 6, 2026, with applicability to January 1, 2026.
Medline Convenience Kits containing Namic RA Syringes recall - death risk
Health Canada issued a Type I recall for Medline Convenience Kits containing Namic RA Syringes due to a potential risk of the syringe rotating adaptor unwinding during use, which may cause procedural delays or, in severe cases, death. Multiple lot numbers across angiographic kits, convenience kits, and tumescent syringe kits are affected. Healthcare providers have been advised to immediately stop using and discard the affected syringes.
Webinar: Interoperability Wars - Information Blocking and EHR Data Access
Clark Hill PLC announces an April 21, 2026 webinar examining the legal and policy landscape of healthcare data interoperability under the Information Blocking Rule. The webinar will address conflicts among health systems, EHR vendors, digital health companies, and national exchange networks over data sharing obligations and regulatory exceptions.
Prop 65 Roundup - April 2026
ArentFox Schiff published its monthly Prop 65 Roundup covering California OEHHA regulatory activity for April 2026. Key items include OEHHA's final report finding synthetic turf crumb rubber poses insignificant health risks, confirmation that vinyl acetate warning requirements are now effective, a private enforcement action regarding lead in agar-agar powder, a new fish consumption advisory for Los Vaqueros Reservoir, and finalized hexavalent chromium health-protective concentration for drinking water.
NAIC Spring 2026 Meeting Update: PBM Working Group
The NAIC PBM Working Group met on March 23, 2026 in San Diego to advance PBM oversight including new examination standards expanding to affiliated entities like GPOs, pricing and rebate pass-through, network adequacy, and a new multi-state SBS complaint module targeting June 2026 availability. Federal reforms under the 2026 Consolidated Appropriations Act will require 100% manufacturer remuneration pass-through to plans in commercial markets and FMV-based flat-fee compensation in Medicare Part D, effective 2028-2029.
CMS FY 2027 IPF proposed rule, comment deadline June 1
CMS FY 2027 IPF proposed rule, comment deadline June 1
CMS Finalizes 2027 Medicare Advantage and Part D Payment Policies
CMS released the Calendar Year 2027 Medicare Advantage and Part D Rate Announcement, finalizing payment policies projected to result in a net average increase of 2.48%, representing over $13 billion in additional MA payments. The finalized policies address coding differentials between MA and Original Medicare and establish three guiding principles for risk adjustment: simplicity, competition, and payment accuracy.
2027 Medicare Advantage and Part D Rate Announcement
CMS released the CY 2027 Medicare Advantage and Part D Rate Announcement, finalizing capitation rates and payment policies. The final policies result in a 2.48% average payment increase, representing over $13 billion in additional payments to Medicare Advantage plans. The announcement includes risk model revisions, Star Ratings changes, and updated normalization factors affecting plan payment calculations.
Acid anhydride compound, polyamideimide resin and film
USPTO granted Patent US12595268B2 to Korea Advanced Institute of Science and Technology (KAIST) for a novel acid anhydride compound and polyamideimide resin and film utilizing the same. The invention provides high thermal resistance, low coefficient of thermal expansion, and colorless transparency properties. The patent contains 11 claims and was filed under Application No. 18517326.
Syngenta patent 12595266B2, pesticide sulfur compounds, Apr 07
Syngenta patent 12595266B2, pesticide sulfur compounds, Apr 07
Benzo nitrogen-containing heteroaromatic ring derivative for complement factor B treatment
The USPTO granted patent US12595270B2 to Xizang Haisco Pharmaceutical Co., Ltd. covering a benzo nitrogen-containing heteroaromatic ring derivative (general formula I) and its use in treating diseases associated with complement factor B activity or expression. The patent includes 8 claims encompassing the compound, stereoisomers, deuterates, solvates, prodrugs, metabolites, and pharmaceutically acceptable salts or co-crystals.
Amide EZH2 Inhibitor Patent - Preparation Method and Medical Applications
The USPTO granted patent US12595267B2 to Shanghai Synergy Pharmaceutical Sciences Co., Ltd. covering an amide small molecule compound that inhibits EZH2 (Zeste gene enhancer homolog 2). The patent protects methods for preparing the compound and its use in treating EZH2-mediated diseases including tumors, myeloproliferative diseases, and autoimmune diseases. The patent contains 11 claims and names 19 inventors.
Hip implant system with metal acetabular cup and ceramic coating
The USPTO granted patent US12594167B2 to Aesculap AG on April 7, 2026, covering a hip implant system comprising an artificial acetabular cup and a metal or alloy acetabular liner with ceramic coating. The patent, with inventors Christian Bader, Janine Fechter, and Jens Schneider, includes 15 claims and was filed on May 28, 2021 under application number 17927972.
Riverpoint Medical quadricep graft suspension patent granted 7th Apr
Riverpoint Medical quadricep graft suspension patent granted 7th Apr
Anti-paravalvular leakage component for transcatheter valve prosthesis
The USPTO granted Patent US12594158B2 to Medtronic CV Luxembourg S.a.r.l. on April 7, 2026, covering an anti-paravalvular leakage component for transcatheter valve prostheses. The invention includes a radially-compressible annular scaffold with a sinusoidal patterned ring of self-expanding material and an impermeable membrane, designed to prevent leakage around implanted valve stents. The patent contains 17 claims.
inQB8 Medical prosthetic heart valve patent granted
The USPTO granted patent US12594160B2 to inQB8 Medical Technologies, LLC for a prosthetic heart valve designed to improve functionality of native heart valves. The invention includes support structures with an elongate central passageway and leaflet elements for blood flow control, configured to biodynamically fix to native leaflets. The patent contains 24 claims and is classified under CPC A61F 2/2418.
Cardiac valve repair devices with annuloplasty features and associated systems and methods
USPTO granted Medtronic, Inc. Patent No. US12594162B2 for cardiac valve repair devices with annuloplasty features and associated systems and methods. The patent covers devices for mitral valve repair including atrial fixation members, spring mechanisms, and methods for contracting the native mitral annulus. Medtronic now holds enforceable intellectual property rights to this cardiac device technology.
Tissue gripper and valve clamping device, US patent granted
USPTO granted patent US12594163B2 to Hangzhou Valgen Medtech Co., Ltd. for a tissue gripper and valve clamping device. The patent covers a connecting frame with two gripping arms designed with varying widths to reduce device weight and pulling force. The filing date was February 22, 2023, with 12 claims.
Prosthetic heart valve for natural blood flow - 4C Medical Technologies
USPTO granted patent US12594164B1 to 4C Medical Technologies for a collapsible prosthetic heart valve implant designed for implantation in heart chambers. The patent covers sizing parameters that allow the implant to conform to heart chamber dimensions based on height and width percentage values, with sizing potentially defined using cardiac imaging.
Expandable implant for adolescent cranium defects, DePuy Synthes
USPTO granted patent US12594165B2 to DePuy Synthes Products, Inc. for an expandable medical implant designed for adolescent cranium defect repair. The patent covers implants with interconnected links that accommodate cranial growth as the patient develops.
Rotary Arc Patella Articulating Geometry - US12594168B2
USPTO granted patent US12594168B2 to Howmedica Osteonics Corp. covering a rotary arc patella implant design with elliptically shaped median ridge articulating surface and dual attachment features for onlay and inlay fixation techniques. The patent includes claims to the implant geometry, bone preparation methods, and implant-bone interface techniques.
Systems and methods for predictable commissural alignment of a replacement heart valve
The USPTO granted patent US12594161B2 to Anteris Technologies Corporation covering a balloon-mounted replacement heart valve prosthesis with a catheter system that allows rotational alignment of the valve commissures during implantation. The patent includes 20 claims covering the catheter handle actuator mechanism enabling predictable commissural alignment. The filing date was December 21, 2023, with application number 18393475.
Low-profile intercranial device patent granted to Longeviti
The USPTO granted Patent US12594166B2 to Longeviti Neuro Solutions, Inc. on April 7, 2026. The patent covers a method for manufacturing a low-profile intercranial device combining a static cranial implant with a functional neurosurgical implant. The device uses virtual design and interdigitating techniques prior to physical assembly.
CLDN18.2 binding molecule patent granted to Sanyou
CLDN18.2 binding molecule patent granted to Sanyou
TfR1 Humanized Antibodies and Cancer Treatment Methods
The USPTO issued Patent US12595310B2 to The Regents of the University of California covering transferrin receptor 1 (TfR1)-binding proteins, including humanized antibodies and methods for treating cancer. The patent, granted on April 7, 2026, includes 20 claims and was filed on November 6, 2020 under Application No. 17775167. The invention relates to humanized TfR1-binding proteins with amino acid substitutions, combination treatments with additional therapeutics, and methods for cancer therapy.
GPC3 antibody patent - methods of use for cancer treatment
The USPTO granted patent US12595314B2 to R.P. Scherer Technologies, LLC for antibodies specific to glypican-3 (GPC3). The patent covers 37 claims including the antibody compositions, nucleic acids encoding the antibodies, methods of manufacturing, and therapeutic uses for treating cell proliferative disorders by enhancing immune responses such as T cell responses to cancer cells.
Analyte Detection Immunoassay Patent Grant
USPTO granted Promega Corporation patent US12596119B2 covering compositions, kits, and methods for performing analyte detection immunoassays. The patent contains 11 claims and lists inventors Nidhi Nath, Rod Flemming, and Marjeta Urh. The patent application was filed on April 26, 2022.
Means and methods for detecting soy allergens
The USPTO granted Patent US12596111B2 to Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. covering methods for manufacturing antibodies that specifically bind to soy Gly m 8 protein and methods for detecting soy material in food or feedstuff preparations using said antibodies. The patent includes 12 claims and covers antibody production via plant-based protein expression, particularly in tobacco plants.
IGF-1R Antibody Compositions for Treatment of Thyroid Eye Disease
The USPTO granted Patent US12595309B2 to Viridian Therapeutics, Inc. covering insulin-like growth factor-1 receptor (IGF-1R) antibody compositions and methods for treating thyroid eye disease (TED). The patent includes 23 claims directed to pharmaceutical compositions and methods of reducing proptosis and Clinical Activity Score (CAS) by inhibiting IGF-1R activity. The patent claims priority to Application No. 18942051, filed November 8, 2024.
Monoclonal antibody matrix metalloproteinase-1 patent granted
USPTO granted Patent US12595315B2 to S&T BIOMED CO., LTD. for a monoclonal antibody specific to matrix metalloproteinase-1. The patent covers the antibody's heavy and light chain variable regions with specific CDR sequences, along with polynucleotides, detection kits, and detection methods. This grant date is April 7, 2026.
TREM2 stabilizing antibodies, Novartis AG, patent grant
The USPTO granted Patent US12595305B2 to Novartis AG on April 7, 2026, covering antibodies that bind to and stabilize human TREM2 protein. The patent names nine inventors and includes 10 claims, establishing Novartis's exclusive rights to this antibody technology.
6-Thio-dG Treatment for Pediatric Brain Tumors
The USPTO granted Patent US12594293B2 to The Board of Regents of The University of Texas System on April 7, 2026, covering the use of 6-thio-dG (a telomerase substrate precursor analog) to treat therapy-resistant telomerase-positive pediatric brain tumors including diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG), and high-risk medulloblastoma. Inventors Jerry Shay and Rachid Drissi developed methods demonstrating that 6-thio-dG induces telomere dysfunction-induced foci, genomic DNA damage, cell death, and tumor growth delay in xenograft models.
Systems for tracking disease progression in a patient
The USPTO granted patent US12593971B2 to Iterative Scopes, Inc. covering systems and methods for tracking colon disease progression over time using video segmentation, feature extraction, and disease evolution prediction. The patent includes 20 claims for technology that processes colonoscopic video data and predicts drug dosage for patients.
Vision screening device including color imaging patent
The USPTO granted Patent US12593977B2 to Welch Allyn, Inc. on April 7, 2026, covering a vision screening device that combines near-infrared radiation imaging with color imaging to detect eye diseases and abnormalities. The device generates composite images by comparing grayscale NIR reflections against expected values to identify ocular conditions. The patent includes 16 claims and covers methods and systems for automated vision screening.
Systems and Methods for Measuring Visual Axis of the Eye
The USPTO granted Patent US12593976B2 to inventor Xiaochun Nie for systems and methods determining angular offset between visual axis and optical axis of the eye. The patent contains 13 claims covering methods for eye measurement used in diagnosis and surgery applications.
Essilor eye refraction system using light field display
USPTO granted Essilor International patent US12593975B2 for a system determining refraction features of both eyes using a light field display device with control circuitry that adjusts light fields based on individual optical aberrations. The patent covers technology for measuring and correcting vision for both eyes simultaneously and includes five inventors: Stephane Boutinon, Estelle Netter, Martha Hernandez-Castaneda, Konogan Baranton, and Gildas Marin.
Endoscope System and Method of Operating the Same - US12593967B2
USPTO granted Fujifilm Corporation patent US12593967B2 for an endoscope system with exposure control based on brightness detection of edge portions of endoscope images. The system calculates brightness information indicating the degree of brightness of edge portions and controls a tracking speed of exposure amount using a suppression coefficient. The patent includes 12 claims covering the exposure control method and system architecture.
Endoluminal Transhepatic Access Procedure Patent Grant
The USPTO granted patent US12593966B2 to Olympus Corporation covering systems, devices, and methods for endoluminal transhepatic access to a patient's pancreaticobiliary system during endoscopic procedures. The patent includes 16 claims for a steerable elongate instrument navigating through body cavities to access the liver and perform operations in the pancreaticobiliary system.
Endoscope with three-wire steering mechanism
USPTO granted patent US12593965B2 to AMBU A/S for an endoscope with a three-wire steering mechanism. The invention includes a handle, insertion cord with bending section, and a steering mechanism using three steering wires radially spaced around the insertion cord axis for controlled navigation. The patent contains 18 claims and covers the system configuration including the endoscope and monitor.
Imaging system and laproscope for imaging an object
USPTO granted patent US12593963B2 to Joshi Innovations GmbH for an imaging system and laproscope featuring dual focus-shifted sensors and multiple optical paths. The patent, filed November 11, 2021 as application 18253495, contains 14 claims covering the dual-sensor optical imaging technology for medical procedures.
Endoscope System and Suction Unit - Olympus Medical Systems
USPTO granted patent US12593961B2 to Olympus Medical Systems Corp. for an endoscope system with an integrated suction unit. The patent covers a design where the suction button, opening, and angle knob are arranged in a specific geometric configuration on the endoscope operation portion. Medical device manufacturers developing endoscopic equipment should consider this patent when designing new products.
Cardiac catheter with magnetic deflection sensor
USPTO granted patent US12594000B2 to St. Jude Medical International Holding for a cardiac catheter with a deformable body that deflects in response to force on the catheter tip. The patent covers a magnetic field sensor and permanent magnet system that detects deflection through changes in magnetic fields, with controller circuitry that associates sensor signals with force measurements. The patent contains 22 allowed claims.
CDC Drug Overdose Data Collection - Comment Request
The CDC has issued a consultation document requesting public comments on drug overdose data collection methods and reporting requirements. The document seeks input on proposed data collection standards that state and local health departments would use to report overdose surveillance data to the CDC. Comments are due by June 8th.
CDC NNDSS Surveillance Update, Comment Deadline June 8
The CDC published a surveillance update to the National Notifiable Diseases Surveillance System (NNDSS), with public comments requested by June 8. The NNDSS is a nationwide system for tracking notifiable diseases reported by state and territorial health departments. Healthcare providers, laboratories, and public health authorities submitting disease data to CDC should review the proposed changes and submit feedback.
Healthcare Task Force Antitrust Enforcement Initiative
The FTC announced a new Healthcare Task Force via Directive dated March 20, 2026, consolidating antitrust enforcement authority across all FTC bureaus. The Task Force will coordinate with DOJ and HHS to target information blocking and anticompetitive practices in healthcare markets. This follows a joint DOJ-FTC appearance at the ONC Annual Meeting in February 2026 signaling coordinated enforcement action.
National Public Health Week Celebration and Local Partnership Recognition
Missouri Governor Mike Kehoe proclaimed April 6-12, 2026, as National Public Health Week. The Missouri Department of Health and Senior Services (DHSS) announced this recognition celebrating the work of public health professionals across the state's 115 local public health agencies. The announcement is informational only and creates no new regulatory requirements or obligations.
AI System for Analyzing Wearable Activity Tracker Health Data
The USPTO granted Patent US12593990B2 to Aetna Inc. on April 7, 2026, covering a system and method for using deep learning algorithms to analyze health data collected from wearable devices such as activity trackers and smartwatches. The system processes input vectors containing monitored parameter data, embedding data from health records, and optionally social determinants and demographic data to generate health condition probability classifiers. Five inventors are named: Naiqian Zhi, Benjamin Wanamaker, Rajiv Bhan, and Sumeet Kumar.
Method and device for determining a coronary microvascular resistance score
USPTO granted Patent US12593988B2 to QFR Solutions B.V. covering methods and devices for determining coronary microvascular resistance scores to assess myocardial tissue perfusion. The patent describes using blood pressure data, flow data, and throughflow geometry data to generate microvascular resistance scores via an electronic output signal for display. Medical device manufacturers developing cardiac diagnostic technologies should review this patent for potential freedom-to-operate implications.
Transmission mode-photoacoustic tomography of the human brain through an acoustic window
The USPTO granted Patent US12593986B2 to the California Institute of Technology covering photoacoustic imaging techniques for transmission mode tomography of the human brain through an acoustic window in the skull. The patent lists inventors Yang Zhang, Sri Sai Narasimha KS Dhara Venkata, and Lihong Wang, with 27 claims. This patent grant establishes enforceable intellectual property rights for diffuse light delivery and acoustic wave detection in brain imaging applications.
Photoacoustic imaging spectral image processing apparatus and method
USPTO granted Patent US12593985B2 to Canon Kabushiki Kaisha for an image processing apparatus and method using photoacoustic imaging technology. The patent covers spectral image acquisition based on photoacoustic signals at multiple wavelengths, contrast agent detection, and display control for distinguishing contrast agent regions from other tissue. The patent has 31 claims and names five inventors.
Smartphone application with pop-open soundwave guide for diagnosing otitis media
The USPTO granted Patent US12594006B2 to Wavely Diagnostic Inc. for a smartphone application system designed to remotely detect otitis media (ear infections) in children for telemedicine use. The patent covers a pop-open soundwave guide that directs audio signals from a smartphone speaker to the eardrum and back to the microphone for analysis. The patent includes 5 claims and was filed on September 30, 2022.
Surgical Vessel Sizing System Patent Grant
USPTO granted patent US12593989B2 to Briteseed, LLC for a surgical system that determines vessel size using optical sensors. The system analyzes pulsatile and non-pulsatile light components to calculate vessel diameter. The patent names 6 inventors and contains 7 claims.
Energy Transmitting Device for Tinnitus Treatment via Bone Conduction
USPTO granted patent US12594007B2 to Circius Pharma AB for an energy transmitting device using bone conduction to treat tinnitus. The patent covers a two-unit system with a first unit producing treatment energy and a second unit securing the device against the patient's skin for bone conductivity transmission. The patent contains 21 claims and was filed on July 26, 2021.
Virus-like Particles Patent Granted to University of Denver
The USPTO granted Patent US12594329B2 to the University of Denver on April 7, 2026. The patent covers virus-like particles, compositions, antibody detection tests using virus-like particles, and methods of producing non-replicating virus-like particles from modified viral genomes. Schuyler B. van Engelenburg is the sole inventor of the 9-claim patent.
Temperature-Optimized Bacillus Strains Patent Grant
The USPTO granted patent US12593849B2 to Chr. Hansen A/S on April 7, 2026, covering new strains of Bacillus paralicheniformis with improved growth rates and plant growth promoting properties. The patent names six inventors including Patricia Dominguez Cuevas and Lars Moelbak, with 21 claims. Filing date was August 28, 2020, under application number 17638152.
Quorum Sensing Compositions and Methods for Microbial Community Modulation
USPTO granted patent US12594307B2 to The Regents of the University of California for quorum sensing compositions and methods for modulating bacterial quorum sensing. The patent covers engineered bacterial strains with multiple activator polypeptide-encoding sequences and methods for tunable dynamics in microbial communities. Inventors include Jeff Hasty, Arianna Miano, and Michael Julius Liao, with applications spanning synthetic biology and therapeutic development.
Single domain antibodies for cancer therapy, Institut Curie
USPTO granted Patent US12594302B2 to Institut Curie covering fully humanized anti-FGFR4 single domain antibodies (sdAbs), functionalized drug nanocarriers, and compositions for cancer therapy. The patent includes 24 claims and covers nucleic acids, vectors, host cells, and immune cells comprising said sdAbs. The invention relates to FGFR4-targeted therapies for treating cancer.
Bispecific CAR Targeting CD19 and CD20 for Cancer Treatment
USPTO granted Patent US12594321B2 to Novartis AG for a bispecific chimeric antigen receptor (CAR) targeting CD19 and CD20 for cancer treatment. The patent covers CAR proteins, encoding nucleic acids, vectors, and methods for treating diseases associated with CD20 or CD22 expression using modified T or NK cells. The patent includes 18 claims and lists 6 inventors.
CD8-specific capture agents, compositions, and methods of using and making
The USPTO granted Regeneron Pharmaceuticals patent US12594350B2 covering stable peptide-based CD8 capture agents for use as detection agents. The patent was issued April 7, 2026, naming Regeneron Pharmaceuticals, Inc. as assignee and Heather Dawn Agnew and Bert Tsunyin Lai as inventors. The application, filed April 4, 2017 (Application No. 15478596), contains 13 claims.
Cisplatin-Eugenol Analogue for Cancer Treatment
The USPTO granted Patent US12594338B2 to King Faisal Specialist Hospital & Research Centre for a cisplatin-eugenol compound with anti-cancer properties. The patent covers the compound composition, synthesis method, pharmaceutical formulations, and methods of cancer treatment. Inventors include Abdelilah Aboussekhra, Ibrahim Al-Jammaz, Basem Al-Otaibi, and Noura N. Alraouji. The patent was filed on July 27, 2023.
Probiotics to prevent cognitive dysfunction
USPTO granted patent US12593863B2 to INTERNATIONAL N&H DENMARK APS covering the use of Lacticaseibacillus paracasei bacteria for preventing or treating cognitive impairments, including those induced by sleep deprivation. The patent names Sile Griffin, Elaine Patterson, and Markus Lehtinen as inventors and includes 5 claims.
HIV Oral Drug Composition Patent
The USPTO granted Patent US12594244B2 to Gilead Sciences, Inc. covering a solid oral dosage form combining tenofovir alafenamide, emtricitabine, and a compound of Formula I for HIV treatment. The patent contains 29 claims and was granted on April 7, 2026, with a filing date of September 29, 2025.
Exosome Production Method for Cancer Therapeutic Delivery
USPTO granted patent US12594344B2 to China Medical University for a large-scale exosome production method using cyclic tensile bioreactors. The patent covers exosomes with anti-HLA-G protein configured as delivery vehicles for cancer therapeutic agents. The grant includes 10 claims and applies to A61P 35/00 (antineoplastic agents) and related CPC classifications.
Topiramate oral liquid suspension patent granted
USPTO granted patent US12594241B2 to inventors Paul Sudhakar and Scott Boyer for an oral liquid suspension formulation containing topiramate (Application No. 18462651). The patent contains 29 claims covering the composition and methods of medical treatment using the formulation. Generic and branded pharmaceutical manufacturers should assess this patent for potential freedom-to-operate implications.
Nanoparticulate drug delivery for therapeutic applications
The USPTO granted Patent US12594347B2 to Duke University for compositions comprising self-assembling conjugates designed for nanoparticulate drug delivery. The patent covers conjugates with albumin binding domains and molecules having log D ≥ 1.5 at pH 7.4, intended for therapeutic applications including cancer treatment (A61P 35/00). Assignee: Duke University; Inventors: Parisa Yousefpour, Ashutosh Chilkoti.
Bioactive benzocycloheptene analogues as PI3K/MK2 inhibitors
USPTO granted Patent US12595234B2 to the Council of Scientific & Industrial Research for bioactive benzocycloheptene analogues that inhibit PI3K and MK2. The patent covers compounds for treating type 2 diabetes, inflammatory conditions, epilepsy, cancer, and CNS disorders. The patent contains 10 claims.
MDM2 Inhibitor Patent Granted to Bahcesehir University
The USPTO granted Bahcesehir University Patent No. US12595232B2 for a novel Mouse Double Minute 2 (MDM2) inhibitor compound. The patent covers formula (I) compounds or pharmaceutically acceptable derivatives for inhibiting MDM2 activity. Application No. 17904403 was filed February 16, 2021, and the patent contains 2 claims.
Thiosemicarbazates and Uses Thereof
The USPTO granted patent US12595233B2 to The Feinstein Institutes for Medical Research on April 7, 2026. The patent covers thiosemicarbazates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides, along with methods for their synthesis and applications in drug discovery, diagnosis, inhibition, prevention, and treatment of diseases. The patent names Yousef Al-Abed and Ahmad Altiti as inventors.
Mesembrine Crystalline Salt Patent Grant
USPTO granted Patent US12595231B2 to Kanna Health Ltd covering novel crystalline salt forms of mesembrine, specifically mesembrine besylate salt. The patent, filed under Application No. 18614136 with 18 claims, covers the chemical compound (C17H23NO3) and its use as a medicament.
STAT3 inhibitor prodrug patent compositions
USPTO granted patent US12594265B2 to Ohio State Innovation Foundation for prodrug compositions inhibiting STAT3 (including STAT3). The patent covers pharmaceutical compositions for treating inflammatory disorders (including multiple sclerosis) and cancers of uncontrolled cellular proliferation. Inventors: Yuhong Yang, Chenglong Li, Michael Racke. Application No. 17821286, 19 claims.
2,6-dioxo-3,6-dihydropyrimidine compound, bactericide, nematicide, and antifungal agent
USPTO granted patent US12593845B2 to Nippon Soda Co., Ltd. on April 7, 2026, covering a 2,6-dioxo-3,6-dihydropyrimidine compound for use as an agricultural and horticultural bactericide, nematicide, and medical/veterinary antifungal agent. The patent contains 4 claims and names 9 inventors including Takaaki Teranishi and Hajime Shimomura.
Fresenius Dali 750 Kit Hemadsorption Device Safety Notice
ANSM issued a safety alert regarding a field safety corrective action conducted by Fresenius Medical Care AG for the Dali 750 Kit hemadsorption device. The safety action is registered under reference R2608923. Users of this medical device have received direct correspondence from Fresenius with details of the corrective measure.
Siemens Atellica CH CK_L Creatine Kinase Reagent Recall
ANSM has recorded a product recall by Siemens Healthcare Diagnostics for its Atellica CH Creatine Kinase (CK_L) biochemical reagent. The recall affects 847 units distributed to medical biology laboratories. This safety action is registered as ANSM reference number R2609472, with the manufacturer issuing recall correspondence on 07/04/2026.
Annual EPSDT Participation Report Information Collection
CMS published a 30-day notice under the Paperwork Reduction Act announcing revisions to Form CMS-416, the Annual Early and Periodic Screening, Diagnostic and Treatment (EPSDT) Participation Report. The collection assesses state effectiveness in providing early health screening, diagnostic, and treatment services to eligible Medicaid children. Public comments on the burden estimate are due May 6, 2026.
Physician Certifications/Recertifications in Skilled Nursing Facilities
CMS published a notice announcing a 60-day public comment period for an extension of an existing information collection regarding physician certifications and recertifications in skilled nursing facilities. The collection is required under Section 1814(a) of the Social Security Act for Medicare payment certifications. Comments on burden estimates are due June 5, 2026.
Rural Health Care Services Outreach Program Measures
HRSA is seeking public comments on proposed measures for the Rural Health Care Services Outreach Program under OMB No. 0906-0009-Revision. The notice requests input on information collection requirements affecting entities participating in rural health outreach. Comments must be submitted by June 8, 2026.
Priority Review Voucher for LOARGYS Rare Pediatric Disease Product
FDA issued a priority review voucher to Aeglea BioTherapeutics for LOARGYS (pegzilarginase-nbln), a rare pediatric disease product designated for arginase deficiency. This voucher grants the holder priority FDA review for a future drug marketing application and is transferable. The document is a routine notice under the Rare Pediatric Disease Priority Review Voucher Program.
Administrative Practices and Formal Hearings Information Collection
FDA issued a notice seeking public comment on an information collection request regarding administrative practices and formal hearings. The agency is requesting feedback on how it manages formal hearing procedures and administrative processes. Comments must be submitted by June 8, 2026.
Information Collection Activities Submission for OMB Review
CMS published a notice submitting information collection activities to OMB for review under the Paperwork Reduction Act. The notice solicits public comments on proposed and existing data collection requirements administered by the agency. Regulated parties have 30 days to submit comments.
Proposed Data Collection Submitted for Public Comment
The CDC has published a notice in the Federal Register proposing a new data collection for public comment. The notice invites feedback from the public and relevant stakeholders on the proposed collection. Comments must be submitted by June 8, 2026.
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention published a routine Paperwork Reduction Act notice seeking public comment on agency information collection requirements. The notice announces a 30-day comment period for unspecified CDC forms. No new compliance obligations are created by this administrative procedure.
Proposed Data Collection Under Paperwork Reduction Act
The CDC published a Federal Register notice seeking public comments on a proposed data collection under the Paperwork Reduction Act. The notice requests input on information collection burden hours and related requirements. Comments must be submitted by June 8, 2026.
WTC Health Program Denies Petitions on Hepatic Steatosis
The CDC's World Trade Center Health Program Administrator has denied Petitions 029, 034, 035, and 062, which requested the addition of hepatic steatosis (fatty liver disease) as a covered health condition under the program. The finding of insufficient evidence was published in the Federal Register (91 FR 17650). This decision affects WTC responders and survivors seeking coverage for this condition.
IVascular Navitian Coronary Microcatheter Recall
ANSM issued a medical device safety recall (R2607706/R2609369) for IVascular Navitian coronary microcatheters manufactured by Life Vascular Device Biotech S.L. The recall affects specific lots and targets pharmacies and healthcare establishments in France. Users should immediately quarantine and return affected products following the manufacturer's instructions.
CVR Management pays $4M for unnecessary vein procedures billed to federal healthcare programs
CVR Management, LLC (dba Center for Vein Restoration) and Center for Vascular Medicine, LLC, along with their CEO, agreed to pay $4 million to resolve False Claims Act allegations. The government alleged the defendants submitted claims to Medicare, Medicaid, and TRICARE for medically unnecessary vein procedures including sclerotherapy, radiofrequency ablation, and endovenous laser ablations. The settlement originated from a qui tam whistleblower lawsuit filed by two former employees.
Healthcare Privacy Complexity Beyond HIPAA and AI Risks
WilmerHale published an analysis noting that healthcare privacy compliance has grown increasingly complex beyond traditional HIPAA frameworks, driven by evolving data security risks and expanding AI opportunities in healthcare. The article identifies meaningful compliance risks across the healthcare ecosystem but does not impose new regulatory requirements.
State AI Legislation Update: Chatbot and Healthcare AI Laws Enacted
Oregon and Idaho enacted chatbot bills into law, while Tennessee signed a healthcare AI bill. All three contain private rights of action with statutory damages. This weekly update tracks state AI legislation affecting private-sector AI developers and deployers, including bill movements in Nebraska, Hawaii, Missouri, Massachusetts, Rhode Island, Louisiana, and South Carolina.
Provider-Based Attestation and NPI Requirements for Off-Campus HOPDs
The Consolidated Appropriations Act of 2026 requires hospitals with off-campus HOPDs to submit provider-based attestations and obtain separate NPIs by January 1, 2028. Non-compliant off-campus HOPDs will lose Medicare payment eligibility and potentially 340B drug pricing access.
CMS Medicare Secondary Payer Enforcement for Workers' Comp Settlements
CMS announced enforcement actions for Medicare Secondary Payer Section 111 quarterly reporting, with penalties effective October 11, 2025 for settlements involving Medicare beneficiaries. CMS will conduct random quarterly audits using AI tools and publicly report results. Self-insured employers and insurance companies with workers' compensation claims settlements must ensure proper reporting to avoid penalties.
Private Equity Healthcare Regulatory Analysis and Trump Policy Outlook
Akin Gump Strauss Hauer & Feld LLP published a regulatory outlook analyzing the impact of Trump administration policies on private equity investments in healthcare and life sciences. The analysis covers projected Medicaid spending cuts exceeding $800 billion under the One Big Beautiful Bill Act, expired ACA subsidies, and emerging opportunities in AI-driven health technology.
CMS Medicare Advantage and Part D Final Rule for Contract Year 2027
The White House released the President's FY 2027 budget request and CMS finalized policy and technical changes to Medicare Advantage, the Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly for contract year 2027. These changes affect MA organizations and Part D plan sponsors.
Measles Exposure Locations Confirmed in Keizer Oregon
Oregon Health Authority and Marion County public health officials confirmed two new measles exposure locations in Keizer, Oregon. The exposure sites are Solar Nails and Pho Keizer, both on River Road North, with potential exposure windows on March 30, 2026 between 12:00 p.m. and 5:30 p.m. Public health officials are urging anyone present at these locations during the specified times to contact their healthcare provider immediately.
Oregon Beach Bacteria Monitoring List 2026-2027
The Oregon Health Authority (OHA) and Oregon Department of Environmental Quality (DEQ) have released the 2026-2027 Oregon Beach Monitoring Program list identifying coastal recreation areas that will be sampled for bacteria during the monitoring season from late May through late September of each year. The biennial list includes beaches where bacteria has been detected or where local partners and the public have requested monitoring. Approximately 14 beaches across Clatsop, Coos, Curry, Lane, and Lincoln counties are designated for monitoring.
Boil Water Advisory Issued for City of McCune After Waterline Break
KDHE issued a boil water advisory for the City of McCune in Crawford County, Kansas on April 5, 2026 following a waterline break that caused loss of pressure in the distribution system. Residents are advised to boil water for one minute before drinking or cooking, and restaurants and food establishments should take precautions. The advisory will remain in effect until bacterial testing at a certified laboratory confirms the water is safe and KDHE issues a rescind order.
RIDOH launches Better State of Healthy campaign
The Rhode Island Department of Health announced the launch of the Better State of Healthy campaign, a public health initiative designed to improve health outcomes across the state. The campaign will focus on promoting healthy behaviors and providing health resources to Rhode Island residents.